Baker Bros. Advisors’s Denali Therapeutics DNLI Stock Holding History

Baker Bros. Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$71.6M	Hold	3,731,695	–	–	0.41%	30
2025 Q4	$61.6M	Hold	3,731,695	–	–	0.36%	35
2025 Q3	$54.2M	Hold	3,731,695	–	–	0.39%	27
2025 Q2	$52.2M	Hold	3,731,695	–	–	0.51%	24
2025 Q1	$50.7M	Hold	3,731,695	–	–	0.56%	20
2024 Q4	$76.1M	Hold	3,731,695	–	–	0.81%	18
2024 Q3	$109M	Hold	3,731,695	–	–	1.13%	14
2024 Q2	$86.6M	Hold	3,731,695	–	–	1.11%	15
2024 Q1	$76.6M	Buy	3,731,695 +1,124,499	+43%	+$21.1M	0.96%	15
2023 Q4	$56M	Buy	2,607,196 +315,193	+14%	+$6.24M	0.64%	20
2023 Q3	$47.3M	Buy	2,292,003 +836,681	+57%	+$21.2M	0.27%	24
2023 Q2	$42.9M	Buy	1,455,322 +366,584	+34%	+$10.3M	0.25%	27
2023 Q1	$25.1M	Hold	1,088,738	–	–	0.14%	34
2022 Q4	$30.3M	Buy	1,088,738 +500,000	+85%	+$14.9M	0.18%	30
2022 Q3	$18.1M	Hold	588,738	–	–	0.12%	52
2022 Q2	$17.3M	Buy	588,738 +500,000	+563%	+$13.1M	0.1%	52
2022 Q1	$2.85M	Hold	88,738	–	–	0.02%	98
2021 Q4	$3.96M	Hold	88,738	–	–	0.02%	97
2021 Q3	$4.48M	Hold	88,738	–	–	0.02%	99
2021 Q2	$6.96M	Hold	88,738	–	–	0.03%	88
2021 Q1	$5.07M	Hold	88,738	–	–	0.02%	94
2020 Q4	$7.43M	Sell	88,738 -10,662	-11%	-$645K	0.03%	83
2020 Q3	$3.56M	Sell	99,400 -5,500	-5%	-$166K	0.01%	87
2020 Q2	$2.54M	Hold	104,900	–	–	0.01%	96
2020 Q1	$1.84M	Buy	+104,900	New	+$2.19M	0.01%	92

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Baker Bros. Advisors's DNLI Position: Q1 2026 in Review

Baker Bros. Advisors held its Denali Therapeutics (DNLI) position steady in Q1 2026 at 3,731,695 shares worth $71.6M. The position accounts for 0.41% of the portfolio, ranked #30.

Baker Bros. Advisors first reported a position in DNLI in Q1 2020 and has held it in 25 quarters since. The position peaked at $109M in Q3 2024. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Baker Bros. Advisors held 3,731,695 shares of Denali Therapeutics worth $71.6M as of Q1 2026.
Baker Bros. Advisors left its Denali Therapeutics share count unchanged in Q1 2026.
Denali Therapeutics made up 0.41% of Baker Bros. Advisors's portfolio in Q1 2026, its #30 holding.
Baker Bros. Advisors first reported a position in Denali Therapeutics in Q1 2020 and has held it in 25 quarters since.
Baker Bros. Advisors's Denali Therapeutics position peaked at $109M in Q3 2024.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.